Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer ...Middle East

SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and...

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer )

Also on site :

• Are You Showering at the Wrong Time? Health Experts Weigh In
• Meghan Markle’s Tea Brand Launch Just Stirred Up Major Drama
• The questions behind the Air India plane crash: What caused it and what happens next?